Drug recalls (page 4)
748 recalls.
- Drogueria San Juan Puerto Rico Isopropyl Alcohol 70% recall (Gasco Industrial Corp.)
DrugClass IIReported July 15, 2026 · Subpotent drug - Gasco Isopropyl Alcohol 70% recall (Gasco Industrial Corp.)
DrugClass IIReported July 15, 2026 · Subpotent drug - Gasco Isopropyl Alcohol 70% recall (Gasco Industrial Corp.)
DrugClass IIReported July 15, 2026 · Subpotent drug - Gasco Isopropyl Alcohol 70% recall (Gasco Industrial Corp.)
DrugClass IIReported July 15, 2026 · Subpotent drug - Methohexital Sodium recall (QuVa Pharma, Inc.)
DrugClass IIReported July 15, 2026 · Failed Impurities/Degradation Specifications - Medline Remedy Specialized Silicone Cream recall (BioMed Laboratories, LLC.)
DrugClass IIReported July 15, 2026 · Failed Impurities/Degradation Specifications; Formaldehyde levels exceeded specification. - Methohexital Sodium for Injection recall (ONESOURCE SPECIALTY PHARMA LIMITED)
DrugClass IIReported July 15, 2026 · Failed Impurities/Degradation Specifications - Glucagon Emergency Kit for Low Blood Sugar recall (Lupin Pharmaceuticals Inc.)
DrugClass IIReported July 8, 2026 · CGMP deviation: OOS result observed for the Gliding Force functionality test during 12-month long term stability testing. - Gemcitabine Injection recall (McKesson)
DrugClass IIReported July 8, 2026 · Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment. - Revitaderm Wound Care recall (Blaine Labs Inc)
DrugClass IIReported July 8, 2026 · CGMP Deviations; product manufactured in the same facility under the same conditions as the product found to be contaminated - Fungal Fusion ERADICATION Solution recall (Blaine Labs Inc)
DrugClass IIReported July 8, 2026 · CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry - TERPENICOL Antifungal Solution recall (Blaine Labs Inc)
DrugClass IIReported July 8, 2026 · CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry - vite20 Antifungal Cream recall (Blaine Labs Inc)
DrugClass IIReported July 8, 2026 · CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry - TERPENICOL Antifungal Cream recall (Blaine Labs Inc)
DrugClass IIReported July 8, 2026 · CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry - TRIPENICOL S Antifungal Solution recall (Blaine Labs Inc)
DrugClass IIReported July 8, 2026 · CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry - TRIFLUENT PHARMA TRIDERGEL Wound Care Gel recall (Blaine Labs Inc)
DrugClass IIReported July 8, 2026 · CGMP Deviations: product manufactured in the same facility under the same conditions as the product found to be contaminated - Revitaderm Wound Care Gel recall (Blaine Labs Inc)
DrugClass IReported July 8, 2026 · Microbial contamination of Non-Sterile Product: samples identified the presence of Lysinibacillus fusiformis and other Bacillus spp - Cinacalcet Hydrochloride Tablets recall (Cipla USA, Inc.)
DrugClass IIReported July 8, 2026 · cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). - Cinacalcet Hydrochloride Tablets recall (Cipla USA, Inc.)
DrugClass IIReported July 8, 2026 · cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). - Cinacalcet Hydrochloride Tablets recall (Cipla USA, Inc.)
DrugClass IIReported July 8, 2026 · cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). - Dextroamphetamine Saccharate recall (Lannett Company Inc.)
DrugClass IIReported July 8, 2026 · Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules. - Lidocaine HCl Injection USP recall (Asclemed USA Inc.)
DrugClass IIReported July 8, 2026 · Lack of Assurance of Sterility - Accucaine recall (Asclemed USA Inc.)
DrugClass IIReported July 8, 2026 · Lack of Assurance of Sterility - Synjardy XR Tablets recall (Boehringer Ingelheim Pharmaceuticals, Inc.)
DrugClass IIReported July 8, 2026 · CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a... - Levothyroxine Sodium Tablets recall (ACCORD HEALTHCARE, INC.)
DrugClass IIReported July 8, 2026 · Subpotent Drug - prednisoLONE Acetate Ophthalmic Suspension recall (Lupin Pharmaceuticals Inc.)
DrugClass IIReported July 8, 2026 · Presence of Foreign Substance - Fexofenadine Hydrochloride Tablets recall (SUN PHARMACEUTICAL INDUSTRIES INC)
DrugClass IIIReported July 8, 2026 · Failed Impurities/Degradation Specifications - IMULDOSA recall (ACCORD BIOPHARMA INC)
DrugClass IIReported July 8, 2026 · Lack of assurance of Sterility: - BD ChloraPrep CLear recall (CareFusion 213, LLC)
DrugClass IIReported July 8, 2026 · Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to... - BD ChloraPrep CLear recall (CareFusion 213, LLC)
DrugClass IIReported July 8, 2026 · Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to... - BD ChloraPrep Scrub Teal recall (CareFusion 213, LLC)
DrugClass IIReported July 8, 2026 · Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to... - BD ChloraPrep Scrub Teal recall (CareFusion 213, LLC)
DrugClass IIReported July 8, 2026 · Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to... - BD ChloraPrep Hi-Lite Orange recall (CareFusion 213, LLC)
DrugClass IIReported July 8, 2026 · Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to... - BD ChloraPrep Hi-Lite Orange recall (CareFusion 213, LLC)
DrugClass IIReported July 8, 2026 · Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to... - ChloraPrep FREPP recall (CareFusion 213, LLC)
DrugClass IIReported July 8, 2026 · Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to... - BD ChloraPrep Clear recall (CareFusion 213, LLC)
DrugClass IIReported July 8, 2026 · Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to... - BD PurPrep recall (CareFusion 213, LLC)
DrugClass IIReported July 8, 2026 · Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to... - BD ChloraPrep Hi-Lite Orange recall (CareFusion 213, LLC)
DrugClass IIReported July 8, 2026 · Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to... - Perampanel CIII Tablets recall (SUN PHARMACEUTICAL INDUSTRIES INC)
DrugClass IIReported July 1, 2026 · Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets. - Povi-One recall (Elevate Oral Care)
DrugClass IIReported July 1, 2026 · sub potency - Lacosamide Tablets recall (Annora Pharma Private Limited)
DrugClass IIReported July 1, 2026 · Presence of a Foreign Tablets: Complaint received, possible mix-up of Selexipag 1000 mcg tablet in a bottle of Lacosamide Tablets USP, 100mg. - BD ChloraPrep FREPP Clear recall (CareFusion 213, LLC)
DrugClass IReported July 1, 2026 · Non-Sterility: Due to presence of Aspergillus penicillioides. And Lack of Assurance of Sterility: Due to wrinkles in the paper lidding which may breach the... - BD ChloraPrep Clear recall (CareFusion 213, LLC)
DrugClass IReported July 1, 2026 · Non-Sterility: Due to presence of Aspergillus penicillioides. - BD ChloraPrep FREPP Clear recall (CareFusion 213, LLC)
DrugClass IIReported July 1, 2026 · Lack of Assurance of Sterility: Due to wrinkles in the paper lidding which may breach the seal area. - BD ChloraPrep Clear recall (CareFusion 213, LLC)
DrugClass IIReported July 1, 2026 · Lack of Assurance of Sterility: Due to wrinkles in the paper lidding which may breach the seal area. - PReye Vitamin See Antioxidant Preservative Free Eye Drops recall (PReye LLC)
DrugClass IIReported July 1, 2026 · Lack of Assurance of Sterility - hydrOXYzine Hydrochloride Oral Solution recall (ANI Pharmaceuticals, Inc.)
DrugClass IIIReported July 1, 2026 · Presence of foreign substance - Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag recall (Central Admixture Pharmacy Services, Inc.)
DrugClass IIReported July 1, 2026 · Incorrect product formulation: bag did not contain copper and famotidine per label. - DULOXETINE D/R recall (Direct Rx)
DrugClass IIReported July 1, 2026 · CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit - Sensipar recall (Amgen, Inc.)
DrugClass IIReported July 1, 2026 · CGMP Deviations - Corlanor recall (Amgen, Inc.)
DrugClass IIReported July 1, 2026 · Presence of Foreign Substance. - Sensipar recall (Amgen, Inc.)
DrugClass IIReported July 1, 2026 · CGMP Deviations - Sensipar recall (Amgen, Inc.)
DrugClass IIReported July 1, 2026 · CGMP Deviations - Corlanor recall (Amgen, Inc.)
DrugClass IIReported July 1, 2026 · Presence of Foreign Substance. - Fenofibrate Capsules recall (Ajanta Pharma USA Inc)
DrugClass IIReported July 1, 2026 · CGMP Deviations - Carton Label: MAJOR recall (The Harvard Drug Group LLC)
DrugClass IIReported July 1, 2026 · Subpotent Drug - Med Pride recall (Dabur India Limited)
DrugClass IIReported June 24, 2026 · CGMP Deviations; deficiencies observed during FDA inspection - Med Pride recall (Dabur India Limited)
DrugClass IIReported June 24, 2026 · CGMP Deviations; deficiencies observed during FDA inspection - Med Pride recall (Dabur India Limited)
DrugClass IIReported June 24, 2026 · CGMP Deviations; deficiencies observed during FDA inspection - Med Pride recall (Dabur India Limited)
DrugClass IIReported June 24, 2026 · CGMP Deviations; deficiencies observed during FDA inspection - Med Pride recall (Dabur India Limited)
DrugClass IIReported June 24, 2026 · CGMP Deviations; deficiencies observed during FDA inspection - Med Pride recall (Dabur India Limited)
DrugClass IIReported June 24, 2026 · CGMP Deviations; deficiencies observed during FDA inspection - Med Pride recall (Dabur India Limited)
DrugClass IIReported June 24, 2026 · CGMP Deviations; deficiencies observed during FDA inspection - Med Pride recall (Dabur India Limited)
DrugClass IIReported June 24, 2026 · CGMP Deviations; deficiencies observed during FDA inspection - Cura Hongos recall (Dabur India Limited)
DrugClass IIReported June 24, 2026 · CGMP Deviations; deficiencies observed during FDA inspection - Rapidol recall (Dabur India Limited)
DrugClass IIReported June 24, 2026 · CGMP Deviations; deficiencies observed during FDA inspection - Lil Drug Store recall (Dabur India Limited)
DrugClass IIReported June 24, 2026 · CGMP Deviations; deficiencies observed during FDA inspection - Circle K recall (Dabur India Limited)
DrugClass IIReported June 24, 2026 · CGMP Deviations; deficiencies observed during FDA inspection - Lucky Super Soft recall (Dabur India Limited)
DrugClass IIReported June 24, 2026 · CGMP Deviations; deficiencies observed during FDA inspection - Lucky Super Soft recall (Dabur India Limited)
DrugClass IIReported June 24, 2026 · CGMP Deviations; deficiencies observed during FDA inspection - Chlorthalidone Tablets recall (Inventia Healthcare Limited)
DrugClass IIReported June 24, 2026 · Failed Dissolution Specifications - Focalin XR recall (Sandoz Inc)
DrugClass IIIReported June 24, 2026 · Labeling: Incorrect or Missing Lot and/or Exp Date - safco SensiCaine-Ultra recall (Keystone Industries)
DrugClass IIReported June 24, 2026 · Defective container:may contain bottles with incomplete seals - PureLife recall (Keystone Industries)
DrugClass IIReported June 24, 2026 · Defective container:may contain bottles with incomplete seals - Dental City TOPICAL ANESTHETIC GEL recall (Keystone Industries)
DrugClass IIReported June 24, 2026 · Defective container:may contain bottles with incomplete seals - Burkhart topical anesthetic gel recall (Keystone Industries)
DrugClass IIReported June 24, 2026 · Defective container:may contain bottles with incomplete seals - DHP Topical Anesthetic Gel recall (Keystone Industries)
DrugClass IIReported June 24, 2026 · Defective container:may contain bottles with incomplete seals - Quala Dental Products recall (Keystone Industries)
DrugClass IIReported June 24, 2026 · Defective container:may contain bottles with incomplete seals - Pearson Quality Topical Anesthetic Gel recall (Keystone Industries)
DrugClass IIReported June 24, 2026 · Defective container:may contain bottles with incomplete seals - Buprenorphine HCl recall (Par Health USA, LLC)
DrugClass IIReported June 24, 2026 · Crystallization; identified as Buprenorphine free base - Aripiprazole Tablets USP recall (Ajanta Pharma USA Inc)
DrugClass IIReported June 24, 2026 · Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg. - Vasopressin 2 Units/2 mL in 0.9% Sodium Chloride recall (IntegraDose Compounding Services LLC)
DrugClass IIReported June 24, 2026 · Subpotent Drug - VistaPharm recall (PAI Holdings LLC)
DrugClass IIReported June 24, 2026 · Does Not Meet USP or OTC Monograph: Product did not meet the Over-the-Counter (OTC) Monograph M023 - VistaPharm recall (PAI Holdings LLC)
DrugClass IIReported June 24, 2026 · Does Not Meet USP or OTC Monograph: Product did not meet the Over-the-Counter (OTC) Monograph M023 - VistaPharm recall (PAI Holdings LLC)
DrugClass IIReported June 24, 2026 · Does Not Meet USP or OTC Monograph: Product did not meet the Over-the-Counter (OTC) Monograph M023 - VistaPharm recall (PAI Holdings LLC)
DrugClass IIReported June 24, 2026 · Does Not Meet USP or OTC Monograph: Product did not meet the Over-the-Counter (OTC) Monograph M023 - Alyacen 7/7/7 recall (Glenmark Pharmaceuticals Inc., USA)
DrugClass IIReported June 24, 2026 · Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities. - BEEKEEPER'S NATURALS Saline Nasal Spray recall (BEEKEEPER'S NATURALS USA INC.)
DrugClass IReported June 17, 2026 · Microbial Contamination of Non-Sterile Products - Budesonide Inhalation Suspension recall (SUN PHARMACEUTICAL INDUSTRIES INC)
DrugClass IIReported June 17, 2026 · Presence of Foreign Substance:This recall has been initiated in response to a product quality complaint reported for black/brown specs and particles within the... - Minocycline Hydrochloride Extended-Release Tablets recall (Ascend Laboratories, LLC)
DrugClass IIReported June 17, 2026 · Failed Dissolution Specifications: An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysis - Gas-X Extra Strength recall (Haleon US Holdings LLC)
DrugClass IReported June 17, 2026 · Chemical Contamination: contamination with a diluted propylene glycol-based coolant from a machine leakage during the packaging process. - GSMS Incorporated recall (Golden State Medical Supply Inc.)
DrugClass IIReported June 17, 2026 · Failed Dissolution Specifications: During 12-month long-term stability testing, subject lot was out of specification (low) for stage 3 dissolution at the... - Zep recall (Zep Inc)
DrugClass IIReported June 17, 2026 · Microbial contamination of sterile products - Primidone Tablets recall (Amneal Pharmaceuticals, LLC)
DrugClass IIIReported June 17, 2026 · Cross Contamination with Other Products: due to a potential for cross-contamination with Acemetacin API due to an issue at the API manufacturer. - Duloxetine Delayed-Release Capsules recall (Breckenridge Pharmaceutical, Inc.)
DrugClass IIReported June 17, 2026 · CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit - Duloxetine Delayed-Release Capsules recall (Breckenridge Pharmaceutical, Inc.)
DrugClass IIReported June 17, 2026 · CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit - Epinephrine Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIIReported June 17, 2026 · Failed Impurities/Degradations Specifications - DOXOrubin Hydrochloride Liposome injection recall (SUN PHARMACEUTICAL INDUSTRIES INC)
DrugClass IReported June 17, 2026 · Presence of Particulate matter: Particulate matter identified as glass. - Xyvona recall (SUN PHARMACEUTICAL INDUSTRIES INC)
DrugClass IIReported June 10, 2026 · Labeling: Not Elsewhere Classified. This recall has been initiated in response to the denial by FDA of marketing the product under the proprietary name Xyvona - Xyvona recall (SUN PHARMACEUTICAL INDUSTRIES INC)
DrugClass IIReported June 10, 2026 · Labeling: Not Elsewhere Classified. This recall has been initiated in response to the denial by FDA of marketing the product under the proprietary name Xyvona